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Abstract
The aim of this study was to describe the many ways in which quality of life (QoL) measurement may potentially be
advantageous in routine clinical dermatology practice. Thirteen members of the EADV Task Force on Quality of Life, eight
dermatologists, three health psychologists, one epidemiologist and one pharmacoepidemiologist, independently listed
all of the ways they thought this may be advantageous. A total of 108 different ways of using QoL information in clinical
practice were suggested (median per participant = 8, range = 4–15), and were classified into 20 descriptive groups.
These were sorted into the following five categories: inform clinical decisions, clinician–patient communication, aware-
ness of skin disease burden, informing the consultation and clinical service administration. The wide range of potential
benefits identified may not only encourage clinicians to use these measures but also highlights many areas requiring evi-
dence to establish the true value of routine use of QoL measures.
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Introduction
The aim of this paper is to identify in what ways health-related
quality of life (QoL) measurement may be of benefit in routine
dermatology clinical practice. Since the first dermatology dis-
ease-specific QoL measure publication1 30 years ago, the assess-
ment of patients’ QoL is now frequently included in
dermatology research studies.2 The measurement of QoL using
validated instruments is recommended in dermatology therapy
guidelines in many countries3–5 and consequently many clini-
cians worldwide have become familiar with these measures.
Anecdotally, some clinicians also use them in their routine clini-
cal work, but about such usage there is very little published and
a systematic review found limited evidence of the impact.6 Some
advantages and disadvantages of routine use of QoL measures in
dermatology clinics7–10 and other specialties11–13 have since been
described.
The European Academy of Dermatology and Venereology
(EADV) Task Force on QoL considers that there are several ways
in which the measurement of QoL in clinical practice may bene-
fit patients, support clinicians’ decision taking and contribute to
delivery of high standards of care, though the evidence for this is
very limited. The aim of this opinion statement is to describe the
many ways in which the use of QoL measures may be advanta-
geous in clinical practice. This opinion statement also aims to
encourage clinicians to use QoL measures in practice and to be a
source of reference. An additional aim is to identify aspects of
the use of QoL measures in clinical practice for which more
research is needed to establish their actual, evidence-based,
value.
Methods
The opinion statement is confined to QoL measures, and does
not address other components of patient-reported outcomes
(PROs), such as those recording symptoms, patient satisfaction
or preference.
All the members of the EADV Task Force on QoL, including
dermatologists, psychologists and other health care profession-
als, were invited to contribute. A draft protocol was reviewed by
all those who expressed interest in the study and changes were
made. Each participant was asked to independently write a list of
all the ways in which they considered QoL measurement is or
could be useful in dermatology clinical practice. This was carried
out before reviewing the literature, in order to encourage origi-
nal thinking among participants and to capture what is actually
practiced. All participants were asked to identify published arti-
cles of relevance that they were aware of in order to support this
opinion statement.
All responses were examined independently by AYF and MSS:
each item was identified and classified. Consensus over classifi-
cation was then reached during three detailed data definition
meetings between AYF and MSS.
Results
All 36 members of the EADV Task Force on QoL were invited to
contribute, 13 (36%) of these took part. Eight dermatologists,
three health psychologists, one epidemiologist and one pharma-
coepidemiologist from 9 European countries participated; 6
(46%) were female.
A total of 108 items were submitted by the 13 participants
(median per participant = 8, range 4–15). These were grouped
under 20 descriptive headings (Table 1) and assigned to five cat-
egories: inform clinical decision, clinician–patient communica-
tion, impact on clinician and patient, informing the
consultation and clinical service administration.
A summary of the key points identified by participants,
with illustrative participant quotations (Appendix), is given
under five main categories and 20 descriptive headings as
follows.
Table 1 The 20 descriptors, given in five categories, of the 108
items mentioned by the 13 participants (median number of items
mentioned per participant = 8, range 4–15).
Number of times
items mentioned
Number of
clinicians
mentioning
these items
1. Inform clinical decisions
Aid treatment decision taking 8 8
Guideline use 1 1
Shared decision taking 4 3
Treatment goals 2 1
Treatment adjustment at follow-up 3 3
Discharge decisions 2 2
2. Clinician–Patient communication
Clinician–Patient relationship 4 3
Clinician–Patient enhanced dialogue 11 7
3. Awareness of skin disease burden: impact on clinician and on
patient
Impact on clinician 20 8
Impact on patient 6 4
4. Informing the consultation
Structured clinical assessment 1 1
Prediction outcomes/prognosis 4 3
Adherence/Compliance 3 3
Screening 7 5
Monitoring 10 9
Education 5 4
Referral to other services 4 4
5. Clinical service administration
Guideline development 1 1
Audit/Clinical audit 6 4
Administration/policy 6 4
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Inform clinical decisions
Aid treatment decision taking Quality of life information may
improve clinical decisions by making them more patient centred.
Quality of life scores can inform decisions relating to choosing
appropriate therapy strategies, whether to discharge or admit.
For example, the Rule of Tens, that includes a QoL score, can be
used to inform decisions over psoriasis therapy (Quote 1).
Guideline use Clinicians in many countries already use QoL
measures routinely as recommended by national guidelines to
inform decisions especially relating to therapy of severe psoriasis
(Quote 2).
Shared decision taking The use of QoL measures may
encourage patients’ involvement in shared decision making.
Patients’ knowledge of nonmedical aspects of their disease is
complementary to the clinician’s expertise in medical factors
(Quote 3).
Treatment goals For many patients, particularly for those with
chronic skin conditions, as well as for the clinician, improve-
ment in QoL is the main treatment goal. Quality of life scores
may guide therapy decisions based on common treatment goals.
They also inform the clinician when considering what potential
risk will be tolerated by the patient (Quote 4).
Treatment adjustment at follow-up Quality of life scores can
aid clinical decision making such as dose adjustment or follow-
up therapy change, e.g., to reduce identified QoL impact more
quickly. Treatment effects can be monitored over several follow-
ups using QoL scores (Quote 5).
Discharge decisions QoL scores can influence the clinician to
take more appropriate discharge decisions, e.g., if scores are
high, delaying discharge or arranging additional support after
discharge (Quote 6).
Clinician–patient communication
Clinician–patient relationship Systematic assessment of
patients’ QoL in outpatients may enhance the clinician–patient
relationship, especially if results are discussed during consulta-
tion. Their use demonstrates to the patient the clinician’s aware-
ness of the QoL impact experienced by the patient and indicates
that the clinician cares about the patient and their preferred out-
comes, not just the disease (Quote 7).
Clinician–patient enhanced dialogue Reviewing the patient’s
responses to the QoL questionnaire items may provide structure
to and direct the clinical discussion to areas of patient concern,
encouraging an overlapping understanding of the disease
between clinician and patient. Use of QoL measures may facili-
tate further discussion on treatment satisfaction, disease burden
and treatment preferences (Quote 8).
Awareness of skin diseases burden
Impact on clinician Use of QoL measures can make clinicians
more aware of the patient’s perspective, the burden experienced
by the patient and their family14 and that lesion severity is not
necessarily correlated with impact on QoL. Clinicians may
become more aware of the likely course of the impact of the con-
dition on the patient and that clinically ‘cured’ conditions may
still impact QoL. At a glance, the domains that are most affected
are identified, so the discussion can be more focused. Issues such
as shame or depression may be revealed and clinicians may be
more likely to counsel the patient and consider referral for psy-
chological help (Quote 9).
Impact on patient Use of QoL measures may help verbalize a
patient’s feelings and give the patient greater insight into and
awareness of their disease and a sense of greater control over
their disease and the consultation. It allows the patient to
express their problems in a wider context than a traditional
symptom-based framework. One participant asserted that the
use of QoL measures in itself may improve treatment outcome.
Score changes over time help patients to be aware of changes
in their disease impact and might make them more interested
in their treatment outcome, leading to improved adherence
(Quote 10).
Informing the consultation: information aid for prognosis,
monitoring, screening, adherence and referral
Structured clinical assessment Structured assessment of QoL
should be a part of the overall assessment of disease severity,
helping to limit observer variation.
Prediction outcomes/prognosis An understanding of the cur-
rent QoL burden on a patient may inform a clinician’s predic-
tions concerning patient therapy adherence, commitment to
long-term therapy and likely therapeutic outcome (Quote 11).
Adherence/compliance If by the use of QoL measures a
patient is aware that their clinician understands their QoL bur-
den, this may improve patient satisfaction and adherence/com-
pliance with treatment (Quote 12).
Screening Use of QoL measures can act as a screening process
to reveal ‘hidden’ physical, psychological and adjustment prob-
lems, to identify patients who may need referral to other special-
ists and to identify patients who may need additional support or
care (Quote 13).
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Monitoring of disease course Regular use of QoL measures
can be used to assist monitoring the course of a condition or the
effectiveness of therapy. Score change can be informative and
alert the physician to the need for consideration of therapy
change. Improvement in QoL may be the most important out-
come of their care for many patients as well as for many clini-
cians (Quote 14).
Education Use of QoL measures, by revealing specific prob-
lems, may allow individualization of educational input to the
patient. Their use may also assist in the education of health care
professionals, e.g., medical and nursing students, to help them
understand the wider burden of skin disease (Quote 15).
Referral to other services Systematic assessment of patients’
QoL, by revealing specific individual problems, may inform
decisions concerning appropriate referral to other specialists or
support services (Quote 16).
Clinical service administration
Guideline use/development The importance of understanding
the QoL impact of skin disease on patients is recognized in many
national guidelines, such as for severe psoriasis,15 where QoL
scores are part of the recommended criteria for therapy decisions
(Quote 17).
Audit/Clinical audit Quality of life measures can be used to
audit service performance from the patient perspective. They
can be used to audit changes to clinical service delivery or effec-
tiveness of educational programmes as well as for comparison of
outcomes of different service providers (Quote 18).
Administration/policy When prioritizing patient referrals to a
clinic, QoL scores could be used to identify patients needing
an urgent appointment because of the high impact of the dis-
ease on their lives. Information from QoL measures may
inform policy makers and inform decisions about which
aspects of a service need to be developed. Quality of life scores
can be used to identify patients needing expensive therapy
and justify its use. The use of structured QoL measures may
allow allied health personnel to act more independently of
physicians. Quality of life measures may be used by patients
as advocacy tools, quantifying and formalizing their com-
plaints (Quote 19).
One participant commented that patients are pleased that
these issues are being tackled and that no patients had ever given
any negative feedback on the use of QoL questionnaires.
Another participant quoted that ‘only when you can measure
something can you talk about it’, and that the focus in medicine
towards management of chronic disease emphasizes the impor-
tance of measuring QoL in clinical practice.
Discussion
Previous authors have addressed the potential benefits of rou-
tinely using QoL measures in a dermatology clinic.7–9 Abeni
et al.8 suggested that the (routine) measurement of QoL would
help to identify patients experiencing major negative impact of
their skin disease and may therefore need treatments that would
not be the usual ‘first-line’ treatment based on clinical severity
alone, or other special support. Salek et al.9 suggested that
improving QoL is becoming an explicit goal of health care in
dermatology consultations. Van Cranenburgh et al.7 identified
why HRQoL assessment is relevant for dermatologic practice
and which patients would benefit most from routine HRQoL
assessment. Aawar et al.10 suggested that using a patient’s QoL
information can lead to optimized treatment decision making,
and be used to prioritize problems, facilitate communication,
screen for potential risks, identify preferences and monitor
response to treatment. Other potential benefits are in the train-
ing of new staff, in clinical audit and for clinical governance.
Cella et al.12 summarized the possible benefits of using
patient-reported outcomes in clinical care as assisting clinical
providers in managing their patients’ care,16 enhancing the
efficiency of clinical practice,17,18 improving patient–provider
communication,17,19 identifying patient needs in a timely
manner17,20 and facilitating patient-centred care.17 All of these
various points were mentioned independently by our study
participants.
Although many dermatologists think they have good insight
into the impact of disease on their patients, the concordance
between clinician-reported measurements of disease burden and
PRO measures appears to be poor.21–23 Little information about
QoL is normally elicited during routine dermatology outpatient
consultations,21 though dermatologists’ clinical decisions in out-
patients concerning psoriasis management are related to the
degree of impact of psoriasis on the patient’s QoL.24 Salek
et al.25 demonstrated that the routine use of QoL measures iden-
tified patients experiencing high impact on QoL. In 29% of con-
sultations where a QoL measure was completed, the clinician
used the QoL information and in 58% of these ‘use’ consulta-
tions the QoL information influenced treatment decision taking,
mainly in patients who were more severely affected than recog-
nized by the clinician. Tabolli et al.26 found that using QoL
assessment routinely in a dermatology unit was well accepted by
patients and clinical staff; however, the actual impact on clinical
activities was limited. Finally, the use of QoL measures may con-
tribute to giving patients ‘perceived control’ over their skin con-
dition, thereby improving the doctor–patient relationship.27.
In dermatology and in other specialties, there is some evi-
dence about possible advantages for routine use of a QoL mea-
sure. For example, routine use of a QoL measure in an oncology
practice raised awareness among physicians of patient function-
ing and facilitated communication without prolonging the con-
sultation.13 There were many episodes of the QoL measure
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identifying issues that might not otherwise have been recog-
nized, including depression, erectile dysfunction and therapy-
induced fatigue. Moreover, a study to compare the use of three
different QoL measures in a breast/prostate cancer clinic28 unex-
pectedly demonstrated that participants from minority racial
groups, with lower education and who had less computer usage,
were more likely to rate the use of a QoL measure favourably.
This suggested that using patient-reported outcome measures in
clinical practice may be an effective approach for addressing the
needs of these groups, a point not raised in our study. Further-
more, the routine use of QoL measures may act as an ongoing
educational process for the clinician, who may gain a greater
insight into the reality of living with skin disease. In exceptional
cases, having the level of QoL impairment documented could
provide evidence of appropriate clinical decision taking should
the appropriateness ever be challenged.
In urticaria management, routine use of QoL measures may
not only improve and standardize medical record keeping and
care, but also release time for the actual physician–patient inter-
action.29 Evers et al.30 emphasized the advantages for personal-
ized health care approaches. For example, QoL instruments
enable the identification of patients who would most likely bene-
fit from treatments. Only those patients at need for help are
offered treatment and patients can be offered treatments specifi-
cally tailored to their adjustment problems. Insight is also gained
into treatment priorities and patient motivation. In addition,
screening of risk and resilience factors may provide clues on
where and how to intervene in a specific patient.
Our study was not designed to document negative aspects of
the use of QoL measures, but it is important to recognize that
there are potential issues. One barrier has been the perception of
increased work burden for the patient and physician,13,31 but
there may be no overall increased work burden for providers if
QoL measures are used.13 It is important that QoL question-
naires are not just completed by but are discussed with patients.
If a patient completes a questionnaire but nothing is apparently
done with it, this reduces motivation to complete another in the
future. However, one study participant stated that patients are
very pleased when QoL measures are used and no patient had
ever given negative feedback to them about their use.
It is likely that the use of computer-based assessment of QoL
will become integrated into clinical practice; the use of such a
tool designed for children has been successfully trialled32: its use
was considered to have the potential to improve patient–physi-
cian communication. However, the implementation of a web-
based system to collect patient-reported outcomes including
QoL encountered some logistical issues and time constraints.33
One practical aspect of the use of QoL measures in routine
clinical practice not mentioned by the participants is the impor-
tance of clinicians to be able to interpret the scores, and also to
have a basic understanding of the minimal clinically important
difference (MCID) of scores. Validated descriptor score bands
and cut-off scores may be helpful to clinicians.34–36 There is
great potential for such information and instant interpretation
of scores to be given automatically to clinicians if QoL measures
were to be used online, both for direct clinical purposes and for
screening.30
Another aspect is the potential in paediatric consultations of
enhancing the communication between children and their par-
ents or carers. By comparing the results of a QoL measure com-
pleted by a child with the assumption of the parent, the parent
may gain a greater understanding of the child’s perspective.37
There are few publications that either describe or suggest the
use of QoL measures in routine clinical practice or describe the
use of QoL information to support clinical decision making in
routine practice. Given that there are many anecdotal reports of
such use, this is an area that requires further documentation, vali-
dation and dissemination of good practice. Muller et al.38 state
that QoL measurement offers major benefits for the treatment of
skin diseases and that first experiences of implementing QoL
measures into practice have been positive. Although we did not
carry out a systematic review regarding advantages and disadvan-
tages of integrating QoL measurements in routine clinical practice
across all medical specialties, it is likely that the advantages and
disadvantages identified in this opinion statement would equally
apply in other medical specialities. However, as the experience of
the contributors was mainly in dermatology, caution should be
taken in the application of the results to other fields of medicine.
In conclusion, the 20 different potential aspects of benefit of
routine use of QoL measures in routine practice that have been
suggested by the study participants provide clear encouragement
for the wider gaining of experience of their use. However, there
is virtually no evidence to back up most of these suggestions,
highlighting a wide array of research questions that need to be
prospectively addressed.
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Appendix 1
Quotes from participants illustrating each
concept
Guide clinical decisions
Quote 1: Aid treatment decision taking
. . . QoL measurement may . . . help dermatologists in mak-
ing more informed, and thus – hopefully – better, decisions
about the treatment/management of their patient’s dis-
eases.
Quote 2: Guideline use
Use as part of guideline protocols, e.g., NICE or BAD
guidelines.
Quote 3: Shared decision taking
By assessing health-related QOL in clinical practice and
discussing the results with the patient, patients with
chronic skin diseases are directly involved in the care pro-
cess. This in turn contributes to shared decision making
and higher patient satisfaction.
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Quote 4: Treatment goals
. . ..necessary in determining the treatment – what are the
treatment goals?
Quote 5: Treatment adjustment at follow-up
. . ..adjusted my therapy in order to reduce sooner the
impact (sometimes, the therapy could be different than we
had thought before measuring the QoL)
Quote 6: Discharge decisions
Use to support clinical decision taking (discharge or fol-
low-up)
Clinician–patient communication
Quote 7: Clinician–patient relationship
It’s a way of showing we care, that we are interested in the
person, as well as the skin condition.
Quote 8: Clinician–patient enhanced dialogue
Insight in HRQoL problems creates an opportunity to
communicate in an empathic and responsive way, thereby
supporting patients in coping with their problems more
effectively. . . .. may be helpful in engaging patients in a dis-
cussion on treatment preferences to allow mutual or shared
decision making.
Awareness of skin diseases burden
Quote 9: Impact on clinician
At a glance we know which domains are most affected (in
this way we can focus on the issues that are affecting the
patient most). . .. Great way of doing psychodermatology
in your everyday practice.
Quote 10: Impact on patient
By filling out a HRQoL questionnaire . . .. patients may
gain more insight into the impact of the skin disease on
their own physical, psychological and social functioning
and well-being. . . .. this insight will increase patients’ self-
awareness, for instance awareness of specific psychological
problems and of specific health care needs. Such awareness,
and the acknowledgement of needs by the dermatologist,
may further empower patients to share and discuss their
problems with significant others, such as a partner, rela-
tives and friends.
Information aid for prognosis, monitoring, screening,
adherence and referral
Quote 11: Prediction outcomes/prognosis
Made a prediction about the future cooperation and
patient’s adherence and commitment for a long-term treat-
ment.
Quote 12: Adherence/compliance
The doctor’s perception of the patient’s quality of life may
influence patient satisfaction with care and adherence to
treatment.
Quote 13: Screening
Use to identify patients who may need psychological sup-
port or referral to nurse specialists.
Furthermore, patients’ needs for additional care, as a sup-
plement to regular dermatological care, can be identified
and addressed.
Quote 14: Monitoring of disease course
. . .to monitor treatment over time, modify treatment if
needed and to determine treatment effectiveness.
Monitoring the course of a condition, or evaluating the
effectiveness of treatment, from the point of view of the
patient is different than from the point of view of the doctor.
An improvement in HRQoL, which is a main treatment
goal for many patients, can be monitored, and may indi-
cate treatment effectiveness.
Quote 15: Education
Individualization of the educational part of consultation
according to patients need.
Quote 16: Referral to other services
To define patients who need consultations of specialists
other than dermatologists (psychologists, psychiatrists etc.).
Clinical service administration
Quote 17: Guideline use/development
Forming of disease-specific recommendations that may
include peculiarities of different age groups, gender differ-
ences and correlations with . . .. patients’ outcomemeasures.
Quote 18: Audit/Clinical audit
Use to assess changes in way clinical service is provided for
patients, (e.g. introduction of nurse-led clinics).
to track . . .. the performance of health care delivery organi-
zations: to evaluate a clinic0s quality of care over time, to
compare the quality of care across clinics.
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Quote 19: Administration/policy
Use to identify patients who have been referred who need
to be seen urgently.
By providing a self-reported significant outcome measure
it allows allied health personnel to act more independently
of physicians, e.g., in nurse-led clinics.
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